| CEO: | Jeremy Skillington |
| CFO: | Ian O’Connel |
| Executive Chairman: | Cathal Friel |
| Independent Non-Executive Director: | Edward Gibson |
| Independent Non-Executive Director: | Luke O’Neill |
| Independent Non-Executive Director: | Brendan Buckley |
| Non-Executive Dir: |
| Address: | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Phone: | +44 (0)20 7183 1499 |
| Website: | http://www.poolbegpharma.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BKPG7Z60 |
| Currency | UK Pounds |
| Share Price | 3.50p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 9.10p |
| 52 Week Low | 2.40p |
| Volume | 573,840 |
| Shares Issued | 697.20m |
| Market Cap | £24.40m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:36 | 15,000 @ 3.46p |
| 16:13 | 50,000 @ 3.48p |
| 15:25 | 54 @ 3.65p |
| 15:08 | 139,554 @ 3.58p |
| 11:02 | 84,872 @ 3.53p |
| CEO | Jeremy Skillington |
| CFO | Ian O’Connel |
You are here: research